Asceneuron is a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases such as the intracellular aggregation of the microtubule-associated protein tau. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders.


We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.

To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).


Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures.

Our executive management team combines research and development excellence with business and fundraising experience to bring innovation to patients. Our highly skilled scientists have extensive experience in all aspects of the drug discovery value chain. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.

Asceneuron pursues a semi-virtual operating model. Our unique biochemical assays, biomarker discovery activities and pharmacology models are pursued in-house, while we collaborate with leading contract research organizations for other activities such as medicinal chemistry. Asceneuron operates in a state-of-the-art facility at the EPFL Innovation Park in Lausanne, Switzerland, in proximity to leading academic institutions in the Lake Geneva area.

Who we are

We are a team of scientists and drug developers supported by a strong syndicate of venture investors and grants from world-renowned patient-focused foundations.